Biocryst Pharmaceuticals Stock News

Wall Street brokerages expect that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report $46.65 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for BioCryst Pharmaceuticals earnings, with estimates ranging from $42.00 million to $50.88 million. BioCryst Pharmaceuticals posted sales of $4.02 million in the same quarter last year, which suggests a []

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has a beta value of 2.47 and has seen 2.07 million shares traded in the last trading session. The company, currently valued at $2.22B, closed the last trade at $13.48 per share which meant it gained $0.3 on the day or 2.28% during that session. The BCRX stock price is -37.09% BioCryst Pharmaceuticals Inc. (BCRX) Is Up 2.28%, As Bears Mark A Gain Read More »

Investors are always on the lookout for untapped opportunities. Looking at the case for BioCryst Pharmaceuticals (BCRX), Oppenheimers Justin Kim thinks that the bi

The Yellow Fever Treatment Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Yellow Fever Treatment Market report is to supply an

Assenagon Asset Management S.A. decreased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 91.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 67,127 shares of the biotechnology companys stock after selling 687,905 shares during the quarter. Assenagon Asset Management S.A.s holdings in []

Related Stocks: TGNA , BDC , EQT , COHU , ICFI , SUPN , ZUO , HOMB , BCRX , ZWS , CNXC , SYNA , ISBC , ORBC , CLDR ,

In the last trading session, 3.1 million BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares changed hands as the companys beta touched 2.47. With the companys per share price at $12.21 changed hands at $1.03 or 9.21% during last session, the market valuation stood at $2.28B. BCRXs last price was a discount, traded about -51.35% off its 52-week Lets Jump Into The BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Forecast Read More »

Related Stocks: BDC , COHU , ICFI , ARNA , ZUO , HOMB , BCRX , ZWS , CNXC , ISBC , SYNA , ORBC , CLDR ,

These eight stocks could rebound nicely over the next year and beyond.

North Star Investment Management Corp. lifted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1.4% during the third quarter, Holdings Channel.com reports. The firm owned 442,900 shares of the biotechnology companys stock after acquiring an additional 6,210 shares during the quarter. North Star Investment Management Corp.s holdings in BioCryst Pharmaceuticals were worth $6,364,000 []

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gran

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)s share price rose 7% on Thursday . The stock traded as high as $12.07 and last traded at $12.06. Approximately 51,577 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 4,236,215 shares. The stock had previously closed at $11.27. Several research analysts have recently []

BioCryst's ORLADEYO has made a great start in the market. BCX9930 has started a set of pivotal trials in PNH.

BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.

Icahn Enterprises and Takeda Pharmaceutical are two intriguing hedges against sky-high inflation rates.